New ‘space hairdryer’ to regenerate heart tissue after bypass surgery
According to WHO, cardiovascular diseases are responsible for 17.9 million annual deaths
Read More
Tag: heart attack
New research suggests women less likely to receive support for cardiogenic shock
Research analysed differences in treatment and survival between women and men with a heart attack and cardiogenic shock
Read More
EU approval for new AI technology that can predict heart attacks
CaRi-Heart technology can identify people at high risk of a fatal heart attack
Read More
AZ’ Farxiga fast-tracked for heart failure following MI
The move is based on the first indication-seeking registry-based randomised controlled trial
Read More
New US approval for AZ’ Brilinta
New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart attack
Read More
New NHS innovations to benefit 750,000
The innovations include a new pre-eclampsia test for pregnant women and an advanced blood test for heart attack diagnosis.
Read More
Novo Nordisk launches type II diabetes awareness campaign
Novo Nordisk UK is launching a campaign to raise awareness of the risk of heart attacks and strokes in people living with type II diabetes.
Read More
NHS ‘MOTs’ missing attendance, uptake and prescribing targets
Attendance, uptake and prescribing rates for NHS health checks are all lower than originally anticipated, according to a systematic review of data published in the British Journal of General Practice (BJGP).
Read More
Women at risk from sub-standard heart attack care
New research part funded by the British Heart Foundation has highlighted stark inequalities between the treatment of men and women with heart attack and the effect this is having on survival.
Read More
Ten percent of men have ‘older’ hearts
A new analysis from Public Health England shows that one in 10 men have a heart age 10 years older than they are, increasing their risk for heart attack or stroke.
Read More
Extended use of AZ’ Brilinta cuts CV death risk 29%
Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-TIMI 54 trial has found.
Read More
Novartis drug cuts cardiovascular risk in heart attack survivors
An experimental antibody being developed by Novartis has cut cardiovascular risk in patients who have survived a heart attack in a late-stage study.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
